Skip to content

Valneva

  • About Us
    About Us Advancing vaccines for better lives Learn More
    • Our Strategy
    • Our Responsibility
    • Our Team
  • Products
    Products Focusing on vaccines for infectious diseases with high unmet needs. Learn More
    • Japanese Encephalitis Vaccine
    • Cholera Vaccine
    • Marketing and Distribution
    • Manufacturing and Services
  • R&D
    R&D Dedicated to innovation in vaccine research and development. Learn More
    • Pipeline
    • Lyme Disease – VLA15
    • Chikungunya – VLA1553
    • Zika – VLA1601
    • Clostridium Difficile – VLA84
  • Investors
    Investors Unlocking value for our shareholders Learn More
    • Events and Presentations
      • Calendar
      • Corporate Presentations
      • Videos and Webcasts
    • Financial Reports
    • Stock Information
      • Stock Price
      • Analysts
      • Shareholder Structure
      • Vienna Stock Exchange Delisting
    • Corporate Governance
      • Corporate Compliance & Ethics
    • Regulated Information
    • Annual General Meeting
    • Contact
  • Media
    Media Press releases, latest news and media resources Learn More
    • Press Releases
    • In The News
    • Scientific Publications
    • Media Kit
    • Media Contact
  • Careers
Contact
  • EN
  • FR
Search

Videos and Webcasts

Valneva H1 2019 Results Webcast
Valneva R&D Investor Day, July 9, 2019 Webcast
Valneva Q1 2019 results Webcast
CEO Thomas Lingelbach comments on Group Strategy Video
CFO David Lawrence about Valneva’s Lyme disease vaccine on www.odjradio.com Webcast
Company Video Video

Valneva

  • About Us
  • Products
  • R&D
  • Investors
  • Media
  • Careers
Related Websites
  • Valneva Canada
  • Valneva UK
  • Valneva Austria
  • Valneva USA
  • Valneva Nordic
Contact
© 2019 Valneva SE. All rights reserved.
  • Legal Notice
  • Cookie Policy
  • Privacy Declaration
  • EU-US Privacy Shield Policy
  • Terms of Use
  • 1907-00-VLA-002 | 11-JUL-2019